Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01434602 · ClinicalTrials.gov registry record · Phase 1
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 86
- Enrollment target
NCT01434602: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT01434602 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 86 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01434602, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 86 participants
- Enrollment target
Study Summary
The goal of Phase 1 of this clinical research study is to find the highest tolerable dose and best schedule of the combination of everolimus and sorafenib that can be given to patients with malignant glioma. The goal of Phase 2 of this study to learn if the combination of everolimus and sorafenib can help to control malignant glioma. The safety of this combination will also be studied in both phases.
Interventions
- DRUG sorafenib
- DRUG everolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2012-10-02 |
| Est. Completion | 2021-07-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01434602
The ClinicalTrials.gov registry entry for NCT01434602 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which sorafenib is the first listed.
NCT01434602 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01434602 about?
NCT01434602 is a clinical study titled "Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas". The goal of Phase 1 of this clinical research study is to find the highest tolerable dose and best schedule of the combination of everolimus and sorafenib that can be given to patients with malignant glioma. The goal of Phase 2 of this study to learn if the combination of everolimus and sorafenib c...
What is the current status of trial NCT01434602?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 86 participants. The study started on 2012-10-02. Estimated completion is 2021-07-13.
What interventions are being tested in trial NCT01434602?
The interventions under investigation include: sorafenib (DRUG), everolimus (DRUG).
Who is sponsoring clinical trial NCT01434602?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.